Table 3 Laboratory findings of the Patients by Treatment groups
From: Effect of Arbidol (Umifenovir) on COVID-19: a randomized controlled trial
Laboratory findings | All patients (n = 100) | Arbidol group (n = 50) | KALETRA group (n = 50) | P Value |
|---|---|---|---|---|
CRP Base, n (%) | 100 (100) | 50 (100) | 50 (100) | 0.6 |
0, n (%) | 16 (16) | 7 (14) | 9 (18) | |
+, n (%) | 29 (29) | 15 (30) | 14 (28) | |
++, n (%) | 29 (29) | 17 (34) | 12 (24) | |
+++, n (%) | 26 (26) | 11 (22) | 15 (30) | |
CRP 7th day, n (%) | 99 (100) | 50 (100) | 49 (100) | 0.2 |
0, n (%) | 33 (33.3) | 17 (34) | 16 (32.7) | |
+, n (%) | 38 (38.3) | 23 (46) | 15 (30.6) | |
++, n (%) | 27 (27.2) | 10 (20) | 17 (34.7) | |
+++, n (%) | 1 (2) | 0 (0) | 1 (2) | |
PCR Base, n (%) | 100 (100) | 50 (50) | 50 (50) | 0.8 |
Positive, n (%) | 51 (51) | 25 (50) | 26 (52) | |
PCR Discharge, n (%) | 97 (100) | 49 (100) | 48 (100) | 0.2 |
Positive, n (%) | 18 (38.2) | 7 (14.3) | 11 (22.9) | |
Oxygen Saturation, % (SD) | < 0.001 | |||
In admission | 84.9 (8) | 85.5 (8.4) | 84.3 (7.7) | 0.4 |
7th day | 93 (4.2) | 93.9 (3.1) | 92 (4.8) | 0.02 |
Erythrocyte Sedimentation Rate, mm/h (SD) | < 0.001 | |||
In admission | 40 (19.9) | 38.7 (19.7) | 41.4 (20.3) | 0.5 |
7th day | 27.8 (17.4) | 23.3 (15.5) | 32.2 (18.2) | 0.01 |
White-cell count, ×109/L (SD) | < 0.001 | |||
In admission | 10.1 (4.9) | 10.5 (4.1) | 9.8 (5.5) | 0.4 |
7th day | 6.7 (2.2) | 6.2 (1.7) | 7.2 (2.5) | 0.03 |
Lymphocyte count, × 109/L (SD) | < 0.001 | |||
In admission | 20.4 (8.7) | 20.3 (8.7) | 20.4 (8.9) | 0.9 |
7th day | 26.3 (10.6) | 24.7 (8.9) | 27.9 (12) | 0.1 |
Neutrophil count, ×109/L (SD) | < 0.001 | |||
In admission | 73.8 (11.2) | 74.6 (9.7) | 73 (12.6) | 0.4 |
7th day | 65.9 (13.2) | 69.1 (11.2) | 62.7 (14.4) | 0.01 |
Neutrophil/ Lymphocyte ratio (SD) | < 0.001 | |||
In admission | 4.7 (3.3) | 4.8 (3.7) | 4.6 (2.8) | 0.7 |
7th day | 3.4 (3.7) | 3.7 (4.3) | 3.2 (2.9) | 0.4 |
AST, IU/L (SD) | 0.9 | |||
In admission | 34.3 (19.9) | 33.8 (23.7) | 34.7 (15.5) | 0.8 |
7th day | 32.5 (15.2) | 31.1 (15.9) | 33.8 (14.4) | 0.3 |
ALT, IU/L (SD) | 0.1 | |||
In admission | 28.8 (16.4) | 28.1 (18.2) | 29.5 (14.6) | 0.6 |
7th day | 30.2 (15.1) | 28.3 (15.6) | 32.2 (14.5) | 0.2 |
Total Bilirubin, mg/dL (SD) | 0.3 | |||
In admission | 0.9 (0.5) | 1 (0.5) | 0.9 (0.4) | 0.3 |
7th day | 1 (0.4) | 1 (0.5) | 1 (0.4) | 0.8 |
Serum Creatinine, μmol/L (SD) | 0.01 | |||
In admission | 1 (0.6) | 1.1 (0.8) | 0.9 (0.2) | 0.1 |
7th day | 0.9 (0.4) | 1 (0.6) | 0.9 (0.2) | 0.1 |
Blood Sodium, mEq/L (SD) | < 0.001 | |||
In admission | 136.3 (3.7) | 136.1 (3.8) | 136.4 (3.6) | 0.7 |
7th day | 140.5 (3) | 140.7 (2.9) | 140.3 (3.1) | 0.5 |
Blood Potassium, mmol/L (SD) | 0.08 | |||
In admission | 3.9 (0.5) | 3.9 (0.5) | 3.9 (0.5) | 0.9 |
7th day | 4 (0.5) | 3.9 (0.4) | 4.2 (0.5) | 0.001 |
TSH, mIU/L (SD) | 0.3 | |||
In admission | 4.2 (1.8) | 4.4 (1.9) | 4.1 (1.7) | 0.3 |
7th day | 4.1 (1.8) | 4.2 (1.9) | 4 (1.7) | 0.5 |